Professor Bengt Erik Haug from the University of Bergen presented the ‘Discovery of LTX-315 – a potential first-in-class oncolytic peptide’ at Basel Life Science week Tuesday Sept 20 2016.
His oral presentation covers how LTX-315 was discovered and generated from the host defence peptide lactoferricin, and some preclinical and clinical highlights achieved with LTX-315, i.e. abscopal effects in preclinical cancer models and clear signs of efficacy in cancer patients in Phase I studies.
The Basel Life Science week conference is an international event that brings together researchers, investors, & policy makers from industry, academia, and not-for-profit institutions. Each year, representatives from more than 45 countries participate in advancing current understanding and applying knowledge to progress the life sciences fields.